Cas:32909-92-5 Sulfametrole manufacturer & supplier

Chemical Name:Sulfametrole

CAS.NO:32909-92-5

Synonyms:UNII-F5AK41IPQG;sulphametrole;Sulfametrole;Benzenesulfonamide, 4-amino-N-(4-methoxy-1,2,5-thiadiazol-3-yl)-;4-sulfanilamido-3-methoxy-1,2,5-thiadiazole;Sulfametrol;N1-(4-methoxy-1,2,5-thiadiazol-3-yl)sulfanilamide;Sulfametrolum;4-Amino-N-(4-methoxy-1,2,5-thiadiazol-3-yl)benzenesulfonamide;3-Methoxy-4-(4′-aminobenzenesulfonamido)-1,2,5-thiadiazole

Molecular Formula:C₉H₁₀N₄O₃S₂

Molecular Weight:286.331

HS Code:2935009090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:496.0±55.0 °C at 760 mmHg

Density:1.6±0.1 g/cm3

Index of Refraction:1.672

PSA:147.05000

Exact Mass:286.019440

LogP:1.64

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like UNII-F5AK41IPQG chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Methoxy-4-(4′-aminobenzenesulfonamido)-1,2,5-thiadiazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Methoxy-4-(4′-aminobenzenesulfonamido)-1,2,5-thiadiazole Use and application,Sulfametrole technical grade,usp/ep/jp grade.

Related News: But when it came to deciding on whether Americans with compromised immune systems should get an extra dose of any COVID-19 vaccine, the CDC said it would need to wait for the FDA to give its regulatory thumbs up first. That could come either through amending its emergency use nods or awarding full approvals. 3-Bromoquinolin-2-amine manufacturers After recently opening one cell therapy plant and breaking ground on another in Massachusetts, Takeda is pivoting westward to beef up production in California. 5-pyridin-4-ylpyridin-2-amine suppliers I look forward to working alongside such an ambitious team who are passionate about using cutting-edge technology to solve the health issues of the future and meet the needs of pharma and biotech companies across the globe.” ethyl 5-methoxy-3-methyl-1H-indole-2-carboxylate vendor & factory The CHMP has agreed on an update of recommendations for monitoring patients. Healthcare professionals should now check their patients for signs of blood cancers at least once a year for 15 years.1,But when it came to deciding on whether Americans with compromised immune systems should get an extra dose of any COVID-19 vaccine, the CDC said it would need to wait for the FDA to give its regulatory thumbs up first. That could come either through amending its emergency use nods or awarding full approvals.